QURALIS
QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS .
QURALIS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2016-12-12
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.quralis.com
Total Employee:
1+
Status:
Active
Contact:
(+1) 617.682.6015
Email Addresses:
[email protected]
Total Funding:
47.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon WordPress Google Universal Analytics Font Awesome
Similar Organizations
1859
1859 is a biotechnology company focusing on the discovery and development of next-generation therapeutics.
Amplo Biotechnology
Amplo Biotechnology is to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction.
Amyloid Solution
Amyloid Solution is a developer of therapy intended to overcome Alzheimer by developing modifying treatments.
Arbor Biotechnologies
Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services.
Biopalette
Biopalette is a operator of a platform intended to offer gene-editing techniques.
BridGene Biosciences
BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
DeepBiome Therapeutics
DeepBiome Therapeutics is an operator of a biotechnology company intended to develop a new drug discovery platform.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Elstar Therapeutics
Fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating multi-functional therapeutics.
Goldfinch Biopharma
Goldfinch is a clinical-stage biotech company focused on discovering and developing precision therapies for patients with kidney disease.
IDEAYA Biosciences
IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality
Illuminare Biotechnologies
Illuminare Biotechnologies is a operator of a biotechnology company intended to reduce risk of nerve damage during surgery.
Latigo Biotherapeutics
Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain.
Maze Therapeutics
Maze Therapeutics is an operator of a biotechnology firm used to focus on translating genetic insights into new medicines.
Microbiotica
Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers.
Ncardia
Ncardia is an Operator of a biotechnology company intended to expedite drug discovery and development process.
Raze Therapeutics
Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Semarion
Semarion leverages microfabrication technology to build smart materials and develop novel cell assaying applications.
Speratum
Speratum is a biotechnology company dedicated to research and development (R&D) of targeted molecular therapies for cancer treatment.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Viralytics
Viralytics is an Australian biotechnology company, listed on the Australian Stock Exchange (ASX:VLA) and is quoted on the OTC market
Current Advisors List
Current Employees Featured
Founder
Investors List
Mitsui Global Investment
Mitsui Global Investment investment in Series A - QurAlis
Sanford Biosciences
Sanford Biosciences investment in Series A - QurAlis
Droia Ventures
Droia Ventures investment in Series A - QurAlis
LS Polaris Innovation Fund
LS Polaris Innovation Fund investment in Series A - QurAlis
MP Healthcare Venture Management
MP Healthcare Venture Management investment in Series A - QurAlis
Inkef
Inkef investment in Series A - QurAlis
Mission BioCapital
Mission BioCapital investment in Series A - QurAlis
Dolby Family Ventures
Dolby Family Ventures investment in Series A - QurAlis
Amgen Ventures
Amgen Ventures investment in Series A - QurAlis
Dementia Discovery Fund
Dementia Discovery Fund investment in Series A - QurAlis
Official Site Inspections
http://www.quralis.com Semrush global rank: 3.71 M Semrush visits lastest month: 3.72 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "QurAlis"
QurAlis - Crunchbase Company Profile & Funding
QurAlis may be growing as evidenced by the company's recent expansion activities and research advancements. The establishment of a European headquarters in The Netherlands suggests an operational expansion into new …See details»
People - QurAlis
Nov 25, 2024 Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical Bio Michelle L. Hastings ... Jason drove the growth of …See details»
Culture - QurAlis
Nov 25, 2024 As pioneers in the realm of neurodegenerative and neurological diseases, QurAlis fearlessly ventures into uncharted territories, guided by our unwavering passion for scientific …See details»
QurAlis Company Profile 2024: Valuation, Funding & Investors
When was QurAlis founded? QurAlis was founded in 2016. Where is QurAlis headquartered? QurAlis is headquartered in Cambridge, MA. What is the size of QurAlis? QurAlis has 79 total …See details»
QurAlis - LinkedIn
QurAlis Presents! QurAlis' chief technology officer Hagen Cramer, was a featured speaker at the TIDES: Oligonucleotides and Peptide Therapeutics Europe 2024 conference held last week in Hamburg ...See details»
QurAlis Company Profile - Office Locations, Competitors ... - Craft
QurAlis is a biotech company that develops precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases. It offers a QR43 platform that allows to investigate …See details»
QurAlis - Funding, Financials, Valuation & Investors - Crunchbase
QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
QurAlis Strengthens Global Presence With Opening of European ...
Jan 3, 2024 QurAlis Corporation logo NEW "The expansion of our operations into Europe represents a new chapter for QurAlis, building upon the tremendous momentum of our …See details»
QurAlis Opens European Headquarters in The Netherlands
Jan 4, 2024 QurAlis focuses on treatments for “patients who have a loss of Kv7.2/7.3, patients who have loss of STATHMIN-2, as well as patients with loss of UNC13A and impairment in …See details»
© 2023 QURALIS CORP
QURALIS –CONFIDENTIAL & PROPRIETARY 19 STMN2: A Genetic Target for the Sporadic ALS Population QRL-201 QURALIS THERAPEUTIC STRATEGY In ALS motor neurons TDP …See details»
QurAlis Expands Leadership Team With Doug Williamson, M.D., as …
Jun 11, 2024 "QurAlis is a mission-driven organization dedicated to bringing transformative therapies to patients with ALS and other serious neurodegenerative diseases," said Mr. …See details»
EQT Life Sciences Co-leads $88 Million Series B Financing in QurAlis
Mar 9, 2023 QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation …See details»
QurAlis Closes $88 Million Series B Financing to Advance Precision ...
Mar 9, 2023 QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation …See details»
Our Story - QurAlis
The QurAlis team together with others in the field cracked the code on sporadic ALS through the identification of major disease drivers linked to TDP-43 pathology. Using human neuronal stem …See details»
QurAlis raises $42 Million Series A Financing to Develop New …
May 13, 2020 QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. We are digging deep into …See details»
QurAlis secures $88M to advance ALS therapies
Mar 16, 2023 QRL-201, the other lead compound, is a first-in-class experimental therapy designed to restore the production of STMN2, a protein found at lower than normal levels in …See details»
QurAlis Strengthens Global Presence With Opening of European ...
Jan 3, 2024 New location in Leiden, The Netherlands will serve as hub for European operations and production of QurAlis’ products for clinical trials through commercialization. ... building …See details»
QurAlis Announces Publication in Molecular Biology of the Cell of …
Dec 23, 2021 QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation …See details»
Patients - QurAlis
Nov 19, 2024 QurAlis is working to change access to better treatment through a precision medicine approach. As the QurAlis team advances our therapeutic programs and continue to …See details»